Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin

被引：20
作者：
Hrovatin, Enzo
Viel, Elda
Lestuzzi, Chiara
Tartuferi, Lucia
Zardo, Fabio
Brieda, Marco
Dametto, Ermanno
Piazza, Rita
Antonini-Canterin, Francesco
Vaccher, Elda
Meneguzzo, Nereo
Nicolosi, Gian Luigi
机构：
[1] AO SM Angeli, Unita Operat Cardiol, ARC, Dip Emergenza, I-33170 Pordenone, Italy
[2] IRCCS CRO Aviano, Pordenone, Italy
来源：
JOURNAL OF CARDIOVASCULAR MEDICINE | 2006年 / 7卷 / 08期
关键词：
cardiotoxicity; chemotherapy; cis-platin; 5-fluorouracil; malignant dysrhythmias;
D O I：
10.2459/01.JCM.0000237914.12915.dd
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The antimetabolite 5-fluorouracil is frequently used in the therapy of various malignancies. Cardiotoxicity has frequently been described during treatment, but there is no common agreement on the need to perform cardiovascular monitoring of patients during 5-fluorouracil administration. We report the case of a young patient with an head-neck cancer on whom a continuous electrocardiogram recording was performed, documenting serious ventricular dysrhythmias in the presence of myocardial ischemia during 5-fluorouracil and cis-platin infusion.
引用
收藏
页码：637 / 640
页数：4
相关论文
共 31 条
[1]   5-fluorouracil-induced severe but reversible cardiogenic shock: A case report [J].
Akhtar, SS ;
Wani, BA ;
Bano, ZA ;
Salim, KP ;
Handoo, FA .
TUMORI, 1996, 82 (05) :505-507
[2]   FLUOROURACIL CARDIOTOXICITY [J].
ANAND, AJ .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (03) :374-378
[3]  
ANDERSON NR, 1993, CANCER, V72, P2287, DOI 10.1002/1097-0142(19931001)72:7<2287::AID-CNCR2820720739>3.0.CO
[4]  
2-5
[5]  
Antonelli D, 1981, G Ital Cardiol, V11, P1758
[6]   Cardiotoxicity of the antiproliferative compound fluorouracil [J].
Becker, K ;
Erckenbrecht, JF ;
Häussinger, D ;
Frieling, T .
DRUGS, 1999, 57 (04) :475-484
[7]  
COLLINS C, 1987, CANCER TREAT REP, V71, P733
[8]   European guidelines on cardiovascular disease prevention in clinical practice -: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2003, 10 (04) :S1-S10
[9]   CARDIOTOXICITY OF HIGH-DOSE CONTINUOUS INFUSION FLUOROURACIL - A PROSPECTIVE CLINICAL-STUDY [J].
DEFORNI, M ;
MALETMARTINO, MC ;
JAILLAIS, P ;
SHUBINSKI, RE ;
BACHAUD, JM ;
LEMAIRE, L ;
CANAL, P ;
CHEVREAU, C ;
CARRIE, D ;
SOULIE, P ;
ROCHE, H ;
BOUDJEMA, B ;
MIHURA, J ;
MARTINO, R ;
BERNADET, P ;
BUGAT, R .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1795-1801
[10]   ADVERSE CARDIAC EFFECTS DURING INDUCTION CHEMOTHERAPY TREATMENT WITH CISPLATIN AND 5-FLUOROURACIL [J].
ESKILSSON, J ;
ALBERTSSON, M ;
MERCKE, C .
RADIOTHERAPY AND ONCOLOGY, 1988, 13 (01) :41-46
1234